Deregulated Signaling Pathways and Innovative Therapeutic Approaches in Cancer
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 May 2026 | Viewed by 47
Special Issue Editors
2. Laboratory of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Thessaly, GR-43100 Karditsa, Greece
3. Faculty of Health and Rehabilitation Sciences, Metropolitan College, GR-41005 Larissa, Greece
Interests: detoxification; N-acetylcysteine; Michael addition; heme; GSH; signaling pathway; cancer angiogenesis; Keap1-Nrf2 signaling; CXC chemokines; NAC-hemin adducts; GSH-hemin adducts; CAR immunotherapy
Interests: pharmacology; toxicology; cancer; c-Myc inhibitors; drug design and development; novel therapies; CAR-T cells; mRNA transfer technologies
Special Issue Information
Dear Colleagues,
A pleiad of deregulated molecular pathways leads to the genesis, promotion, progression, and finally metastasis of the cancer tissue. Nowadays, the recent advances in this field have offered key therapeutic approaches to halt or even, in some cases, eliminate the cancer cells. However, due to the high prevalence and mortality, different cancer types, and resistance to drugs, as well as cancer stemness, innovative approaches are still needed.
This Special Issue targets collecting new data from either side of research (molecular, biochemical, bioinformatics, meta-analysis, systemic review, preclinical data, and clinical data) related to the mechanism(s) of action of novel anti-cancer therapeutics. In addition, articles related to the potential druggable mechanisms of tumorigenesis and/or drug resistance are also well accepted. Our potential aim is to gather recent data on the molecular biology of cancer, with potentially significant impact on anti-cancer therapeutics.
In particular, key signaling pathways often misbalanced in cancer are, among others, the epidermal growth factor receptors (EGFR1, HER2, etc.), immune-related signals such as PD-L1, cell cycle-related signals such as the cyclin-dependent kinases, signaling transduction cascades such as the PI3k-Akt-mTor and the Ras-MAPK pathway, repair mechanisms (PARP) and telomerase, angiogenetic and metastatic cytokines (such as CXCL8), antioxidant mechanisms such as the KEAP1-NRF2 anti-oxidative system, the mechanisms of the epithelial–mesenchymal transition and stem cell renewal, key oncogenic transcription factors (c-myc, HIF), and tumor repressor partners (p53).
Among the latest therapeutic approaches are the cancer vaccines, CAR-T and CAR-NK therapies (like Kymriah and Aucatzyl), immune checkpoint inhibitors (like Nivolumab and Pembrolizumab), targeted (agnostic) therapies to specific molecular targets (like Erlotinib and Vemurafenib), epigenetic approaches, and mAbs conjugates, bispecific Abs, and others.
Both Special Issue Editors, Professor Dr. Ioannis S. Pappas and Dr. Sofia Georgiou-Siafis, are experienced at the molecular basis of cancer, signaling pathways, and metabolic profiles, as well as novel anti-cancer pharmacological approaches. Both Special Issue Editors welcome new submissions in this issue.
Dr. Sofia Georgiou-Siafis
Dr. Ioannis S. Pappas
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anti-cancer therapeutic approaches
- innovative therapeutics
- molecular biology
- deregulated signaling pathways
- oncogenes
- tumor repressor partners
- antioxidant mechanisms
- mAbs
- targeted therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
